HaEmek Medical Center, Israel is conducting an Observational study in 7000 participants in order to to determine whether there is a need for preparative fasting prior to contrast-enhanced computed tomography (CT)/
Shenzhen Geno-Immune Medical Institute is conducting a Phase I/II clinical trial of gene transfer for treating Beta-thalassemia using a self-inactivating lentiviral vector to functionally correct the defective gene(s) in 20 participants. The objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
Universidade Federal Fluminense is conducting an Observational study in 200 participants in order to propose cervicothoracic transcutaneous electrical nerve stimulation (TENS) as a non-pharmacological therapy to attenuate cardiac sympathetic overdrive in patients with heart failure.
Barts & The London NHS Trust is conducting an Observational study in 150 participants in order to identify new predisposition genes for endocrine tumours. The focus initially is on pituitary adenomas including growth hormone-secreting tumors (somatotrophinomas) and prolactin secreting tumours (prolactinomas), but the authors extended work to other pituitary tumour cases/families.
Alfasigma S.p.A. is conducting an Interventional study in 882 participants in order to evaluate the safety and efficacy of two different doses of a delayed release formulation of rifaximin, versus placebo, for the prevention of recurrence of acute diverticulitis and diverticular complications in patients with a recent episode of acute diverticulitis.
The removed wisdom teeth and tissue are thrown away as medical waste. Oral health researchers want to collect teeth and tissue for research and encourage dentists at the National Institutes of Health to improve their skills in oral surgery. This study will collect the teeth and tissue of people who need to have oral surgery to remove their wisdom teeth.
Investigators aim to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
A double-blind, placebo-controlled, randomized withdrawal, multicenter clinical trial will be evaluating the safety and efficacy of cariprazine in the treatment of Bipolar I disorder patients whose current episode is manic or depressive with or without mixed features.
This randomized, blinded, the vehicle-controlled, dose-finding research study will evaluate the effectiveness and safety of two concentrations (0.5% and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in adolescent and adult subjects with atopic dermatitis (eczema). Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and application frequency in future clinical studies.
This is an open label, multi-center, randomized phase I/II study of MLN0128 versus standard sorafenib. Eligible subjects in the phase I trial will receive MLN0128 in escalating doses. Eligible subjects in the phase II trial will be 1:1 randomized to either the MLN0128 arm or the sorafenib arm.